Taken together, our research demonstrates that MARCO blockade may be used as a tactic to increase the efficacy of treatments that target the adaptive branch of the immune response, supporting and expanding the application of immune checkpoint therapy in RCC. Here, MARCO is linked to renal cell adenocarcinoma.